Back Other Health News Other Health News Topics Human Papillomavirus (HPV)

ICAAC 2013: Risk Factors and Screening for HPV Anal Dysplasia

About two-thirds of gay men and one-fifth of women tested in Spain were found to have abnormalities that could progress to anal cancer, and both groups would benefit from more widespread and accurate testing, researchers reported at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) this month in Denver. The men's study found that human papillomavirus (HPV) type 39 was a key risk factor.


HPV can trigger abnormal cell growth ranging from warts to cancer. Certain high-risk or oncogenic types, including HPV-16 and HPV-18, cause anal, cervical, and other genital cancers. These typically begin as low-grade dysplasia (also known as squamous intraepithelial lesions or intraepithelial neoplasia) and can progress to high-grade lesions and then carcinoma if not treated. Lower-risk types including HPV-6 and HPV-11 cause genital warts. However, high-risk types do not always cause dysplasia, low-grade neoplasia does always progress to high-grade lesions or cancer, and lesions may regress on their own without treatment.

Anal cancer is more common among people with HIV than it is in the general population, and prevalence is especially high among men who have sex with men (MSM). Although cervical cancer is considered an AIDS-defining malignancy, anal cancer is not so classified. Regular cervical Pap tests are recommended for both HIV positive and negative women to catch abnormalities at an early stage, but clinical practices for screening, preventing, and treating anal cancer vary widely.

Carmen Hidalgo from Hospital Universitario Virgen de las Nieves in Granada, Spain, and colleagues reported findings from studies looking at HPV infection, anal dysplasia, and predictive factors in men and women with HIV.

Men Who Have Sex With Men

The men's study, presented at an oral session, looked at prevalence of and risk factors for high-grade or stage 2-3 anal intraepithelialneoplasia (AIN) or anal cancer (carcinoma in situ) among HIV positive MSM. The researchers assessed the accuracy of HPV PCR testing for more than a dozen high-risk and low-risk types, cytology (testing for cell abnormalities, as done with a Pap smear), and anoscopy (examination of anal-rectal tissue with a magnifying device). They also compared anoscope-guided cytology vs cytology samples taken with swab.

The analysis included 103 participants in a prospective cohort study that screened HIV positive MSM for anal dysplasia from April 2010 through September 2012 using all 3 methods.

The average age was 36 years and the mean and nadir (lowest-ever) CD4 T-cell counts were 645 and 387 cells/mm3, respectively, indicating well-preserved immune function. Most (85%) used antiretroviral therapy (ART). Half were smokers -- a know risk factors for HPV-related cancer -- and about 40% had anal warts. All the men reported anal sex, they had a median of 1.5 sexual partners during the study, and 70% said they used condoms.


  • Overall, the researchers found that one-third to one-half of the men had low-grade squamous intraepithelial lesions (LSIL) or stage 1 AIN, and around 5% to 10% had high-grade squamous intraepithelial lesions (HSIL) or stage 2-3 AIN, depending on the method used:

o   Anal cytology using swab:

*  LSIL: 53%;

*  HSIL: 5%;

*  Atypical squamous cells of undetermined significance (ASCUS): 5%;

*  Normal: 33%.

o   Anoscopy (histology):

*  AIN 1: 44%;

*  AIN 2-3: 10%;

*  Carcinoma in situ: 11%;

*  Normal: 36%.

o   Cytology with anoscope:

*  LSIL: 36;

*  HSIL: 7%;

*  ASCUS: 6%;

*  Normal: 50%.

  • In a univariate analysis looking at separate risk factors, older age and infection with HPV types 6, 39, or 42 predicted high-grade AIN or anal cancer.
  • In a multivariate analysis, however, HPV-36 was the only independent risk factor to reach statistical significance, conferring more than a 10-fold higher risk (odds ratio 10.51).
  • Neither smoking nor CD4 count were associated with greater risk in this study, in which CD4 cells were uniformly high.
  • For each testing method, the researchers calculated sensitivity (ability to detect true cases), specificity (ability to rule out if not present), positive predictive value (PPV, or proportion of correct positive diagnoses), and negative predictive value (NPV, or proportion of correct negative diagnoses):

o   Anal swab cytology: 94%, 42%, 31%, and 97%, respectively;

o   Cytology with anoscope: 90%, 61%, 40%, and 96%, respectively;

o   High-risk HPV testing: 83%, 15%, 24%, and 77%, respectively;

o   Anal swab cytology and high-risk HPV: 79%, 41%, 28%, and 88%, respectively;

o   Anal swab cytology and/or high-risk HPV: 100%, 15%, 24%, and 100%, respectively.

"In our HIV positive MSM cohort, the association of the oncogenic HPV genotype 39 with other [high risk] HPV genotypes was the main risk factor associated with high-grade AIN and/or carcinoma in situ," the researchers concluded.

With regard to testing methods, anoscopy-guided cytology does not improve the diagnosis of dysplasia, and "for this reason, we do not think that it should be included in the screening protocol."

HIV positive MSM "should be systematically tested for dysplastic lesions with anal cytology and HPV PCR," they summarized.

If cytology is abnormal, irrespective of the grade of dysplasia, histological evaluation of the lesion should be performed using anoscopy, they added. But if cytology is normal, HPV PCR screening should be done, and if high-risk HPV is found, the patient should also be referred for anoscopy.

Asked if anal screening could be done less often after a series of negative tests -- as is the case for HIV negative women undergoing cervical screening -- Hidalgo Tenorio said she recommends ongoing screening every year for this population.

Session moderator Judith Aberg asked about the unexpectedly high rate of HPV-39, speculating whether widespread vaccination against HPV types 16 and 18 might allow other types to take over as major causes of cancer. Hidalgo Tenorio did not have an answer, but to date HPV vaccines have mostly been given to young women, and more recently young men, so coverage is likely still low in this population. She noted that new vaccines are under study that will protect against more HPV types than current vaccines.

Women with HIV

Hidalgo Tenorio's team also presented a poster looking at the prevalence of and risk factors for anal dysplasia among a cohort of women in southern Spain, comparing rates to those of men who have sex with men.

While cervical abnormalities are a known risk for women with HIV, anal dysplasia may be equally or more common, though it is not regularly screened for. The researchers noted that HIV positive women have a 14-fold higher risk of anal neoplasia than HIV negative women.

This cross-sectional analysis looked at HIV positive women and MSM receiving medical care at a single center in southern Spain between December 2008 and December 2012. The men were the same group described above.

The 45 women were a bit older, with an average age of 43 years. Mean and nadir CD4 T-cell counts were 692 and 223 cells/mm3, respectively, and most (93%) were taking ART. A majority (71%) were smokers, 22% had anal warts, and 27% were coinfected with hepatitis C (compared with only 4% of the men). They reported a median of 1 sexual partner during the study, 53% said they used condoms, and only 22% reported anal sex.


  • 23% of the women had low-risk HPV types and 34% had high-risk types, compared with 71% and 85%, respectively, among the men.
  • Looking at high-risk types among women, 5% had HPV-16, 5% had HPV-18, 9% had HPV-51, and 2% had HPV-53; for men, the corresponding prevalence rates were 27%, 17%, 18%, and 15%, respectively.
  • More than three-quarters of the women (79%) had normal cytology by anal swabs, compared with one-third of the men.
  • 8 women (19%) had LSIL, none had HSIL, and 1 (2%) had ASCUS.
  • In a univariate analysis, significant risk factors for anal dysplasia were presence of either low-risk of high-risk HPV types, with HIV viral load and CD4 count being of borderline significance.
  • In a multivariate analysis, however, presence of anal or genital warts was the only independent risk factor (OR 11.5)

Rates of dysplasia and anal HPV infection in this cohort of HIV positive women were significantly lower than those of HIV positive MSM, but even they are high enough to justify screening regardless of virological or immunological status, the researchers concluded.

They did not answer the question put forth in their title -- whether anal dysplasia among people with HIV is a matter of sexual behavior or gender -- but HPV is sexually transmitted, and the women in this study were much less likely than the gay men to have had anal sex.



C Hidalgo Tenorio, M Rivero Rodriguez, C Gil Anguita, et al. Prevalence of and risk factors for high-grade intraepithelial neoplasia (HGIN) and anal cancer in an HIV MSM Spanish Cohort. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013). Denver, September 10-13, 2013. Abstract H-1532.

C Hidalgo Tenorio, M Rivero Rodriguez, C Gil, et al. Is HPV anal dysplasia in HIV patients a matter of sexual behaviour or gender?
53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013). Denver, September 10-13, 2013. Abstract H-1270.

HPV Vaccine Prevents Oral Infection, May Lower Risk of Mouth and Throat Cancer

Vaccination against human papillomavirus (HPV) types 16 and 18 reduced oral infection by more than 90% in a large study in Costa Rica, which is likely to bring down the rate of mouth and throat cancers in years to come, according to a report in the July 17, 2013, online edition of PLoS ONE.


CROI 2013: Cancer Incidence After Starting Antiretroviral Therapy [VIDEO]

Rates of AIDS-related cancers start to fall not long after initiation of antiretroviral therapy (ART), but non-AIDS cancers rise with increasing time on therapy, according to study findings presented last week at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.


IAS 2013: HPV Vaccination May Prevent Anal Cancer in Older Gay Men

A large number of infections with anal cancer-associated strains of human papillomavirus (HPV) among older gay men could be prevented with the use of HPV vaccines, Australian research reported at the recent 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) in Kuala Lumpur. A related analysis showed that high-grade pre-cancerous cell changes were common but often resolved spontaneously.


U.S. Cancer Rates Fall Overall, but Some HPV-associated Cancers Rise

Deaths due to all types of cancer combined decreased for men and women of all racial/ethnic groups in the U.S., according to a joint "Annual Report to the Nation," published in the January 7, 2013, advance edition of the Journal of the National Cancer Institute. Incidence of oral and anal cancer increased, however, leading the report authors to call for wider use of human papillomavirus (HPV) vaccines.


Lower HPV Prevalence Among Young Women Credited to Vaccine

The prevalence of human papillomavirus (HPV) among teenage women in the U.S. has declined substantially in recent years -- falling by more than 50% -- coinciding with widespread HPV immunization starting in 2006, according to a CDC study described in the June 19, 2013, advance edition of the Journal of Infectious Diseases.


Human Papillomavirus Vaccination Can Protect Many Women with HIV

HIV positive women may benefit from immunization against cancer-causing human papillomavirus (HPV) types, even though they are likely to have been exposed to some types of the virus previously, according to a study in the November 1, 2012, Journal of Acquired Immune Deficiency Syndromes. A majority of study participants remained susceptible to the most common high-risk types, HPV-16 and HPV-18.alt

Star Calls Attention to Oral Sex Throat Cancer Link, Raising Awareness of HPV Vaccine

Actor Michael Douglas' claim that his throat cancer was caused by oral sex has brought new attention to the link between human papillomavirus (HPV) and oral cancer, as well as heightened interest in HPV vaccination for both girls and boys. Recent studies suggest that spouses of people with oral cancer are not themselves at higher risk, 2 vaccine doses may work as well as 1, and vaccination has already reduced genital warts in Australia.


Topical Cidofovir Effective and Well-tolerated for Anal and Vulva Neoplasia

A topical formulation of the antiviral drug cidofovir (Vistide), best known as a treatment for cytomegalovirus (CMV), also appears effective for short-term treatment of high-grade anal and vulva cancer caused by human papillomavirus (HPV) in people with HIV, according to a report in the October 1, 2012, advance online edition of AIDS. alt

Does Human Papillomavirus Contribute to Lung Cancer?

A small proportion of lung cancers may be caused by the same high-risk strains of human papillomavirus (HPV) associated with cervical and anal cancer, according to recently reported study findings, which could help explain an apparent link between higher lung cancer rates and immune deficiency in people with HIV.


HIV Is a Major Contributor to Increase in Anal Cancer among U.S. Men

Increased incidence of anal cancer during the past 3 decades among men in the U.S. has been strongly influenced by the HIV epidemic, although a similar association was not observed for women, researchers reported in the October 5, 2012, advance edition of the Journal of the National Cancer Institute. alt

CROI 2013: Random Anal Biopsies Improve Detection of Pre-cancerous Lesions

Performing random anal biopsies increases the rate of diagnosis of high-grade squamous intraepithelial lesions (HSIL) during high-resolution anoscopy, researchers from Mt. Sinai School of Medicine in New York City reported at the recent 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013).alt

ICAAC 2012: Progression of Anal Neoplasia is Common among Gay Men with HIV

Nearly 40% of HIV positive men with low-grade anal neoplasia may progress to high-grade neoplasia or anal cancer, according to a Spanish study presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) this week in San Francisco. Younger age and shorter duration of HIV infection were risk factors for worsening disease.alt

CROI 2013: Researchers Look at Neurological Complications among People with HIV

Data from a small, yet well-designed trial to evaluate whether particular antiretroviral therapy (ART) regimens penetrate the central nervous system (CNS) and enhance neurocognitive performance were among several interesting findings regarding neurological complications among people with HIV presented at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) this month in Atlanta. Another study looked at similarities between Alzheimer's disease and neurocognitive impairment in people with HIV.


AIDS 2012: Human Papillomavirus Doubles Risk of HIV infection

Pre-existing human papillomavirus (HPV) infection is associated with a 2-fold increase in the risk of HIV acquisition in women, and risk also rose for both heterosexual and gay/bisexual men, according to an 8-study review presented at the recent XIX International AIDS Conference (AIDS 2012) in Washington, DC, and published in the August 7, 2012, advance online edition of AIDS.alt

CROI 2013: Statins for People with HIV -- How Sweet Is It?

Statins may help reduce co-morbid conditions such as cardiovascular disease and lower mortality for some people with HIV, but with a possible trade-off of higher diabetes risk, according to a series of studies presented and discussed at 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) this month in Atlanta.


HPV Vaccine Provides Herd Immunity to Unvaccinated Women

The human papillomavirus (HPV) vaccine can offer protection to girls and young women who did not themselves undergo immunization, a phenomenon known as "herd immunity," according to a study published in the July 9, 2012, advance online edition of Pediatrics. Widespread immunity against high-risk altHPV types 16 and 18 may result in lower rates of cervical and anal cancer in years to come.

CROI 2013: HIV+ Men at Increased Risk for Co-morbid Conditions Regardless of Age

 Men with HIV in a large cohort of U.S. veterans were more likely to develop cardiovascular disease, end-stage kidney disease, and certain cancers compared with HIV negative people, but not at earlier ages, according to a report presented at the 20th Conference on Retroviruses and Opportunistic Infections this month in Atlanta.


Chronic Gum Disease Linked to HPV-related Head and Neck Cancers

Chronic periodontitis, or inflammation of the gums, is associated with a great risk of squamous cell carcinomas of the mouth and throat that contain human papillomavirus (HPV), according to a study published in the June 18, 2012, advance online edition of Archives of Otolaryngology - Head and Neck Surgery.alt

CROI 2013: Heart Disease Rises Only Slighter Faster with Age for People with HIV

The risk of cardiovascular disease among HIV positive men in D:A:D rose from age 40-45 to 60-65, but only slightly more rapidly than in the general population,researchers reported at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) last week in Atlanta. A related analysis found that the likelihood of death after a heart attack has fallen over time.


Researchers Identify Origin of Cervical Cancer Caused by Human Papillomavirus

Researchers have identified a population of cells in the uterine cervix that appears to give rise to dysplasia and cancer caused by human papillomavirus (HPV), according to a report in the June 11, 2012, Proceedings of the National Academy of Sciences.alt